NCT00127140View on ClinicalTrials.gov

A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Lymphoma
Interventions
DRUG

vorinostat

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00127140 - A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) | Biotech Hunter | Biotech Hunter